Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05541861 · ClinicalTrials.gov registry record · Phase 1
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
A Phase 1 study, sponsored by BioNTech SE.
- Completed
- Registry status
- Phase 1
- Development phase
- 383
- Enrollment target
NCT05541861 is a Phase 1 study that has completed, run by BioNTech SE. The registered enrollment target is 383 participants.
The verdict
NCT05541861, a Phase 1 study, has completed, sponsored by BioNTech SE.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 383 participants
- Enrollment target
Study Summary
This was an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to select a safe and tolerable dose and to evaluate BNT162b4 + BNT162b2 Bivalent (original/Omicron BA.4/BA.5) when given as Dose 1 and Dose 2 (booster) in Cohorts 1 and 2 and BNT162b4 + BNT162b2 Monovalent (OMI XBB.1.5) when given as Dose 2 (booster) in Cohorts 3a, 3b, 4a, and 4b, and 30 microgram (mcg) BNT162b4 when given alone as Dose 1 and Dose 2 in Cohort 5. The trial used a staggered dosing process schema, i.e., enrollment into the next higher dose level was done sequentially and subject to safety data from the previous dose levels, with sentinel participants in Cohorts 1, 2, 3a, and 4a. Cohort 3b investigating the same dose level as cohort 3a but in participants aged \>55 years was opened after safety data for participants aged 18-55 years in Cohort 3a had been reviewed. Enrollment into Cohorts 4a and 4b was opened after safety data for Cohort 3a and 3b had been reviewed. Cohort 5 participants were not randomized and received two doses of BNT162b4 alone after which a safety review was performed after all participants received Dose 2 in this cohort. BNT162b4 plus BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) was co-administered (as a single injection). BNT162b4 alone was administered as a single injection.
Interventions
- BIOLOGICAL BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg
- BIOLOGICAL BNT162b4 5 mcg
- BIOLOGICAL BNT162b4 10 mcg
- BIOLOGICAL BNT162b4 15 mcg
- BIOLOGICAL BNT162b4 30 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2022-11-08 |
| Est. Completion | 2024-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05541861
The ClinicalTrials.gov registry entry for NCT05541861 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg is the first listed.
NCT05541861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05541861 about?
NCT05541861 is a clinical study titled "Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People". This was an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to select a safe and tolerable dose and to evaluate BNT162b4 + BNT162b2 Bivale...
What is the current status of trial NCT05541861?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 383 participants. The study started on 2022-11-08. Estimated completion is 2024-11-22.
What interventions are being tested in trial NCT05541861?
The interventions under investigation include: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg (BIOLOGICAL), BNT162b4 5 mcg (BIOLOGICAL), BNT162b4 10 mcg (BIOLOGICAL), BNT162b4 15 mcg (BIOLOGICAL), BNT162b4 30 mcg (BIOLOGICAL).
Who is sponsoring clinical trial NCT05541861?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.